Related Experiment Video
Updated: Jul 8, 2026
10:16
Point-of-care CRISPR-based Diagnostics with Premixed and Freeze-dried Reagents
Published on: August 16, 2024
CRISPR-based diagnostics for ESKAPE drug-resistant bacteria: From proof-of-concept to point-of-care
Yongkang Mu1, Yuanzhan Yang1, Yumeng Niu1
1School of Medical Science and Engineering, Beijing Institute of Technology, Beijing, 100081, China.
Talanta
|July 6, 2026
Summary
CRISPR diagnostics show promise for rapid detection of ESKAPE pathogens, crucial in the antimicrobial resistance crisis. Overcoming challenges in sample prep and multiplexing is key for point-of-care application against these drug-resistant bacteria.
Area of Science:
- Microbiology
- Biotechnology
- Molecular Diagnostics
Background:
- ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species) are a major threat in the antimicrobial resistance (AMR) crisis.
- Existing diagnostic methods are too slow and lack adaptability for point-of-care (POC) use against increasingly pan-resistant bacteria.
- CRISPR/Cas systems offer programmable specificity and signal amplification for rapid nucleic acid detection, but face hurdles in clinical translation for ESKAPE pathogens.
Purpose of the Study:
- Critically assess the current state of CRISPR-based diagnostic assays for ESKAPE pathogens.
- Analyze how different CRISPR systems (Cas9, Cas12, Cas13, Cas14) and amplification strategies meet POC testing demands.
- Identify barriers and emerging solutions for translating CRISPR diagnostics from research to bedside application.
Main Methods:
- Review and analysis of existing literature on CRISPR-based diagnostics for ESKAPE pathogens.
- Evaluation of various CRISPR systems and amplification techniques for sensitivity, multiplexing, and operational simplicity.
- Identification of key challenges including sample preparation, multiplex detection, and reagent stability.
Main Results:
- CRISPR systems demonstrate potential for rapid, specific nucleic acid detection of ESKAPE pathogens.
- Significant challenges remain in sample preparation, multiplexing capabilities, and reagent stability for practical POC deployment.
- Emerging solutions like microfluidics, lyophilized reagents, and AI-driven interpretation show promise for overcoming these barriers.
Conclusions:
- Advancing CRISPR diagnostics for ESKAPE pathogens requires addressing trade-offs between assay performance and operational simplicity.
- Integration of microfluidics, stable reagents, and AI can facilitate the development of next-generation POC diagnostic tools.
- Strategic development is crucial for enabling rapid, precise, real-time detection of drug-resistant ESKAPE pathogens to combat the AMR crisis.
Related Concept Videos
01:28CRISPR/Cas9 Genome Editing
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
01:59CRISPR
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced Short...